सभी अध्ययन
आमंत्रण द्वारा नामांकनप्रेक्षणीय

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

This study is gathering information on Refixia/REBINYN, a treatment for males with Haemophilia B. We want to understand how it works and if there are any side effects when used over several years. If you join, you'll continue to receive your usual treatment as decided by your doctor. You'll have regular clinic visits just as you do now, where your doctor might check your health and ask about any side effects. You'll also be asked to keep track of any bleeds and your treatment, and to fill out questionnaires about your quality of life and physical activity. Your participation could last for 4 to 9 years, but you are free to leave the study at any time without affecting your medical care.

एक नजर में

स्थिति
आमंत्रण द्वारा नामांकन
प्रायोजक
Novo Nordisk A/S
नामांकन लक्ष्य
60
प्रारंभ
01 अप्रैल 2019
अनुमानित पूर्णता
15 दिसम्बर 2027

यह अध्ययन किस बारे में है?

This research study is for males who have Haemophilia B and are being treated with a medicine called Refixia/REBINYN. Haemophilia B is a rare inherited disorder where your blood doesn't clot properly due to a lack of a specific protein called Factor IX. This can lead to longer bleeding after injuries.

The main aim of this study is to collect information on how well Refixia/REBINYN works to prevent bleeds and whether it causes any side effects when used regularly over a long period. We already know this treatment helps, but understanding its long-term effects is very important for patients' health and well-being. This information helps doctors understand the best ways to care for people with Haemophilia B.

By taking part, you'll be contributing to valuable knowledge that could help many other people living with Haemophilia B in the future. The study is designed to fit in with your normal medical care, so it shouldn't feel too different from your usual check-ups.

मुख्य निष्कर्ष

  • This study collects long-term information on a Haemophilia B treatment called Refixia/REBINYN.
  • It aims to understand how well the medicine works and if there are any side effects over time.
  • Only males with Haemophilia B already using or starting Refixia/REBINYN can join.
  • You'll continue your usual treatment and have regular check-ups.
  • You'll track bleeds and fill out questionnaires about your quality of life.
  • Participation lasts 4-9 years, with the option to withdraw at any time.

कौन पात्र हो सकता है?

This study is specifically for males of any age who have Haemophilia B and who are already using or are about to start using Refixia/REBINYN as a regular treatment to prevent bleeds. Importantly, the decision to start or continue this particular medicine must have been made by you (or your parent/guardian if you're under 18) and your doctor, completely separate from whether you join this study.

This means if your doctor has already decided that Refixia/REBINYN is the best treatment for you, then you might be able to join. You'll need to be able to understand what the study involves and agree to take part by signing a consent form.

You won't be able to join if you've already taken part in this specific study before. Also, if you're known to be allergic to Refixia/REBINYN or similar medicines, or if your body has developed a problem where it makes antibodies against Factor IX (called an "inhibitor"), you wouldn't be able to participate. If you have difficulties understanding or cooperating due to mental health issues, or a language barrier that can't be overcome, you wouldn't be eligible either.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. क्या आप पुरुष हैं?
  2. Do you have Haemophilia B?
  3. Are you currently using or about to start Refixia/REBINYN as regular treatment?
  4. Has your doctor already decided this treatment is right for you, separately from the study?
  5. Have you not previously taken part in this specific study?
  6. Are you able to understand the study information and agree to take part?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part in this study, you'll continue with your regular treatment of Refixia/REBINYN, just as prescribed by your study doctor. Your clinic visits will be much like your usual appointments. During these visits, your doctor might do some routine tests if they think it's helpful.

They will also ask if you've had any side effects since your last visit. We'll ask you to keep a record of any bleeds you have, how you treat them, and when you take your regular Refixia/REBINYN dose. You'll also be asked to fill out questionnaires about how your Haemophilia B affects your daily life and your ability to be physically active.

Your participation in this study could last anywhere from 4 to 9 years, depending on when you start. Remember, you can choose to leave the study at any time, for any reason, without it affecting your medical care.

संभावित जोखिम और लाभ

Participating in this study might not offer direct health benefits beyond the treatment you would already be receiving. However, the information gathered will be very valuable in helping doctors and researchers understand more about the long-term effects of Refixia/REBINYN for people with Haemophilia B. This improved understanding can lead to better care for others in the future. There are no additional medical risks from being in the study beyond those associated with your standard treatment and routine clinic visits. You have the right to withdraw from the study at any point, and doing so will not change the quality of your current or future medical care.

स्थान (30)

  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    सत्यापित पोस्टकोड
    वियना, ऑस्ट्रिया
  • Cliniques universitaires Saint-Luc - Service Hématologie
    सत्यापित पोस्टकोड
    ब्रुसेल्स, बेल्जियम
  • UZ Antwerpen - UZA - Kinderhemato-Oncologie
    सत्यापित पोस्टकोड
    एडेगम, बेल्जियम
  • UZ Leuven - Hart en Vaatziekten
    सत्यापित पोस्टकोड
    ल्यूवेन, बेल्जियम
  • University of Calgary Cumming School of Medicine
    सत्यापित पोस्टकोड
    कैलगरी, कनाडा
  • Univ of Alberta Hospital Res
    सत्यापित पोस्टकोड
    एडमोंटन, कनाडा
  • CancerCare Manitoba
    सत्यापित पोस्टकोड
    विन्निपेग, कनाडा
  • Health Science Centre
    सत्यापित पोस्टकोड
    St. John's, Canada
  • Hamilton Health Sciences Corp, Ontario
    सत्यापित पोस्टकोड
    हैमिल्टन, कनाडा
  • Hamltn Hth Sci/McMstr Child Hosp
    सत्यापित पोस्टकोड
    हैमिल्टन, कनाडा
  • The Hospital for Sick Children
    सत्यापित पोस्टकोड
    टोरंटो, कनाडा
  • KBC Zagreb_Hematology
    सत्यापित पोस्टकोड
    ज़ाग्रेब, क्रोएशिया

सामान्य प्रश्न

What is Haemophilia B?

Haemophilia B is a health condition where your blood doesn't clot properly because you are missing a protein called Factor IX, leading to more bleeding.

What is Refixia/REBINYN?

Refixia/REBINYN is a medicine used to treat Haemophilia B by replacing the missing Factor IX, helping your blood clot better and preventing bleeds.

Will I get a different treatment in this study?

No, you will keep receiving the same Refixia/REBINYN treatment that your own doctor has already decided is best for you.

मैं अध्ययन में कितने समय तक रहूँगा?

You could be in the study for 4 to 9 years, depending on when you start, but you can leave at any time.

Can I stop being in the study?

Yes, you can leave the study at any time for any reason, and it won't affect your medical care.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "A Study Following Males With Haemophilia B on Prophylaxis Wi…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.